Chinese CDMO WuXi STA is to build a new pharmaceutical clinical and commercial manufacturing complex on a 78-hectare campus in Middletown, Delaware. This has been supported by the Delaware Prosperity Partnership, other state departments and local government bodies, and received grants from the Delaware Strategic Fund.
Novasep has announced a €6.1 million investment to modernise API manufacturing at its site in Mourenx, south-west France. This followed on shortly after a €4 million investment had been announced at its main HPAPIs site at Le Mans.
Via the former investment, Novasep will install new equipment and revamp clean rooms for API isolation at Mourenx, creating seven new jobs. The company said that this will “enhance Novasep’s flexibility and develop a high-performance capacity for the custom manufacturing of innovative therapeutic molecules”.
AlzChem, the only supplier of speciality nitriles outside China, has completed a €12 million expansion that took 15 months and will increase capacity by 50%. This is particularly targeted at the pharmaceutical and agrochemical markets and is expected to lead to additional sales of €10-20 million/year, depending on the product mix.
The Biden administration has announced plans to tackle the US’s dependency on imports for critical medicines, with a new strategy that will seek to drive the ‘reshoring’ of some manufacturing. This follows a multi-industry review of key supply chains, occasioned by an executive order in February.
W.R. Grace & Co., which has itself just agreed to be acquired by Standard Industries Holdings for approximately $7 billion, has announced two further transactions. It has completed the $570 million acquisition of Albemarle Fine Chemistry Services and the expansion of its manufacturing plant in Kuantan, Malaysia.
Cambrex has completed the upgrade of the kilo lab at its facility in Tallinn, Estonia, manufacture pharmaceutical intermediates to cGMP standards. The company said that this would “accelerate the progression and tech transfer of projects within the early clinical development phases”.
Speciality life science materials player Aceto has made two further acquisitions, both in the pharmaceutical field, in the form of Oregon-based Cascade Chemistry and Finar in India. Terms were not disclosed in either case.
These bring the total number of acquisitions the new-look firm has made to five in the past 15 months. “With each of our acquisitions, Aceto looks to add companies that enhance our business capabilities and support our growth strategy, while aligning with our core business values,” said CEO Gilles Cottier.
